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Private Payer Perspective—Author Response to Letter to the EditorTo the Editor—Thank you for allowing us to respond to the letter by
Liedgens et al. regarding our cost-effectiveness analysis of duloxetine
in chronic low back pain (CLBP) [1]. We are pleased to address their
concerns. We do so by using the same numbering as in their letter.1. Liedgens et al. question that study populations for opioid pain
trials may not be comparable to populations in trials for other
treatments. In the review of the CLBP oral treatment trial
literature for our meta-analysis, we found that trials, regardless
of treatment, speciﬁed patient inclusion criteria of baseline and/
or ﬂare pain scores of at least a 4 or 5 on a 0 to 10 scale, that is,
at least moderate pain. The trials with the highest baseline pain
scores were for etoricoxib [2,3], a COX-2 inhibitor, not for
tapentadol or another opioid. Moreover, patients receiving
etoricoxib experienced the greatest pain relief [2,3].2. We thank Liedgens et al. for bringing the dosing of tapentadol
extended release (ER) to our attention and acknowledge that on
further research it should have been lower, thus reducing the
model’s initial 3-month, subsequent 3-month, and discontinua-
tion drug costs for tapentadol. However, reducing the dosage to
levels below those seen in clinical trials, as suggested by Liedgens
et al., would place the efﬁcacy of tapentadol ER in doubt. We have
conducted a revised analysis with lowered tapentadol ER dosing,
and it does not change the primary ﬁndings of our analysis.
Duloxetine remains the only nondominated treatment other
than naproxen, with an incremental cost-effectiveness ratio of
approximately $59,500 per quality-adjusted life-year. Tapentadol
remains themost costly treatment, including the costs of adverse
events. If we remove all comparators but tapentadol ER and
oxycodone ER from the model, with the revised dosing we
estimate an incremental cost-effectiveness ratio for tapentadol
ER of approximately $158,000 over oxycodone ER.3. Liedgens et al. are incorrect in claiming that an oxycodone
daily dose of 10 to 30 mg was used in our model. The model’s
dosage was 10 to 30 mg bid (twice daily). (See Table 1 of the
publication at http://dx.doi.org/10.1016/j.jval.2012.12.006.)4. Liedgens et al. incorrectly state that the rate of proton pump
inhibitor usage associated with opioids in our model was
higher than that for nonsteroidal anti-inﬂammatory drugs.
In fact, it was less than half that for the nonsteroidal anti-
inﬂammatory drug naproxen. (See Table 1 of the publication
at http://dx.doi.org/10.1016/j.jval.2012.12.006.) Kelly et al. [4]
was cited in our publication for the rate of proton pump
inhibitor usage among US opioid users. It is further supported
by Williams et al. [5].5. Liedgens et al. pose questions concerning discontinuation
costs. The discontinuation cost given in Table 1 http://dx.doi.
org/10.1016/j.jval.2012.12.006 is the cost per patient who dis-ial support: This research was supported by Eli Lillycontinues, rather than a cost for every patient, as presumably
interpreted by Liedgens et al. This was estimated as the drug
cost during tapering off the opioid, which is recommended in
tapentadol prescribing information to reduce withdrawal
symptoms. Liedgens et al. are correct that the rate of disconti-
nuation appears to be lower for tapentadol than for oxyco-
done. This is reﬂected in the model. The probability of discon-
tinuation, however, is unrelated to the cost per patient who
discontinues.6. Our manuscript was submitted in August 2012. The article by
Dart et al. [6] mentioned in the Liedgens et al. letter was pub-
lished in December 2012, and therefore was unavailable for
our study.
We acknowledge that the dosing of tapentadol ER should have
been lower. However, a revised analysis with lowered tapentadol
ER dosing does not change the primary conclusion that dulox-
etine may be a cost-effective treatment for CLBP that dominates
all strong opioids. The other issues raised by Liedgens et al. are
plainly in error or not supported by the literature that was
available at the time of the analysis. We stand by our research,
analysis, and conclusions.Ronald C. Wielage, MPH
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Objectives: Depression is associated with reduced cognitive function and signiﬁcant healthcare costs; however, the extent to which
these two are related remains unclear. This study compared follow-up healthcare costs for major depressive disorder patients with
and without cognitive dysfunction after antidepressant (AD) initiation. Methods: A large US health plan afﬁliated with OptumInsight
was used to identify depressed patients with a newly prescribed AD who could be surveyed to assess cognitive function. Patients with
neurological diseases associated with cognitive dysfunction were excluded. Patients were mailed a survey invitation and consent
form. Patients maintained eligibility by conﬁrming a depressive diagnosis and no excluding diagnoses. Consenting, eligible patients
were interviewed by telephone and completed 4 cognitive function tests. Patients were classiﬁed as “cognitive normal (CN)” or
“cognitive dysfunction (CD)” based on test scores relative to normative data. All-cause healthcare costs in the 3 months post-AD
initiation were calculated from pharmacy and medical claims. T-tests compared 3-month costs of CN versus CD. Gammamodels with
log link compared healthcare costs between CD and CN patients, adjusting for race, sex, age, education, employment, depression
severity, and comorbidities. Results: 13,537 patients were invited to participate in the study and 564 patients maintained eligibility
and completed the study. Patients were mostly female (80%), mean age was 41 years, 98% had a high school degree or higher, and 84%
were employed. A total of 45% (n¼255) met criteria for CD. Mean healthcare costs were $3,053 for all patients. Costs were $3,948 for the
CD group compared to $2,312 for the CN (p ¼ 0.113). In the gammamodels with costs as the outcome, CD patients had costs 1.46 times
higher than CN patients (95% CI: 1.12, 1.92)(p¼0.0059). Conclusions: In this study population, healthcare costs were signiﬁcantly higher
in patients with cognitive dysfunction compared to those without cognitive dysfunction.
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